Eton Pharmaceuticals, Inc. 8-K

What Happened

• On March 19, 2026, Eton Pharmaceuticals, Inc. (ETON) filed a Form 8‑K under Item 2.02 to announce its financial results for the fourth quarter and the twelve months ended December 31, 2025.
• The company issued a press release reporting those quarterly and full‑year results; the press release is attached to the 8‑K as Exhibit 99.1 (and the filing includes the related Inline XBRL cover file).

Key Details

• Filing date: March 19, 2026 (Form 8‑K, Item 2.02 and Item 9.01).
• Periods covered: Fourth quarter and full year ended December 31, 2025.
• Disclosure format: Results were announced by press release (Exhibit 99.1) and the filing includes interactive XBRL cover data.

Why It Matters

• Earnings and full‑year results provide concrete information about Eton’s revenue, profitability and financial condition for 2025 — key metrics investors use to assess company performance.
• Investors should read the attached press release (Exhibit 99.1) for the specific figures (revenue, net income/loss, cash position, and any management commentary) and monitor subsequent SEC filings for more detailed financial statements and disclosures.